The U.S. Centers for Disease Control and Prevention (CDC) is seeking information on the manufacturing surge capacity for countermeasures against chemical, biological, radiological and nuclear (CBRN) threats according to a solicitation notice it issued Tuesday.
The CDC is aiming to gain this information from the pharmaceutical community on 500 mg tablets of Amoxicillin with units of 60-, 100-, 150- and 300-tablet quantities; 500 mg of Ciprofloxicin HCL in quantities of 20 or 100 tablets and Doxycycline hyclate 100 mg tablets with quantities of 20 or 100.
The CDC plans to use information that is gathered to enhance and update stockpiling strategies that supports overall preparedness and health response needs.
Respondents should only provide needed data areas. The following should be included in submissions: a point of contact and their email and phone information; the DUNS number; identification as a large or small business; federal supply schedules and all NAICS codes that are relevant. Respondents should indicate the manufacturing capabilities in a month, year and surge time frame, the item's name and description, the size specifics on the bottles or other packaging and any barriers that may impact production.
The CDC asks that any proprietary information is clearly indicated as such and to separate that information from the rest of the document. Submissions should be submitted electronically to VRB7@CDC.gov by 1 p.m. EST on March 3.